Popular terms

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      

This page is updated frequently with new Codon-related patent applications.




Date/App# patent app List of recent Codon-related patents
05/19/16
20160137699 
 Recombinant fusion antigen gene, recombinant fusion antigen protein and subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus patent thumbnailnew patent Recombinant fusion antigen gene, recombinant fusion antigen protein and subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus
The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (prrsv). A recombinant fusion antigen gene, which encodes glycoprotein gp5 with truncated n′-terminal decoy epitope, a linker sequence and membrane protein m, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein.
National Pingtung University Of Science And Technology


05/19/16
20160137656 
 Processes for making hydrocodone, hydromorphone and their derivatives patent thumbnailnew patent Processes for making hydrocodone, hydromorphone and their derivatives
Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160137655 
 Processes for making hydrocodone, hydromorphone and their derivatives patent thumbnailnew patent Processes for making hydrocodone, hydromorphone and their derivatives
Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160136156 
 Immediate release pharmaceutical compositions comprising oxycodone and naloxone patent thumbnailnew patent Immediate release pharmaceutical compositions comprising oxycodone and naloxone
The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts.. .
Purdue Pharma L.p.


05/19/16
20160136154 
 Extended release hydrocodone acetaminophen and related methods and uses thereof patent thumbnailnew patent Extended release hydrocodone acetaminophen and related methods and uses thereof
The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily.
Abbvie Inc.


04/28/16
20160115487 
 Cell-free synthetic incorporation of non-natural amino acids into proteins patent thumbnailCell-free synthetic incorporation of non-natural amino acids into proteins
The present disclosure provides methods for incorporating at least one non-natural amino acid into a polypeptide using a cell-free protein synthesis which includes a cell-free extract and is deficient in endogenous trna. The methods include providing the synthesis system with at least one non-natural amino acid, at least one orthogonal trna and one orthogonal aminoacyl-trna synthetase which aminoacylates the corresponding orthogonal trna with the non-natural amino acid.
Brigham Young University


04/28/16
20160115463 
 Codon modified amylase from bacillus akibai patent thumbnailCodon modified amylase from bacillus akibai
The present invention relates to an isolated synthetic polynucleotide encoding the mature amylase ax856 from bacillus akibai, using codon modified polynucleotide constructs for the expression of the amylase.. .
Novozymes A/s


04/21/16
20160108372 
 Pestivirus replicons providing an rna-based viral vector system patent thumbnailPestivirus replicons providing an rna-based viral vector system
Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins e1, e2, ems or c protein, and consequently cannot generate infectious virus particles.

04/21/16
20160106740 
 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106739 
 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106738 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/14/16
20160102128 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160096875 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160095853 

Use of binders for manufacturing storage stable formulations


The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.. .
Purdue Pharma L.p.


03/24/16
20160083763 

Method of random circular permutation by mucp-isc and mucp-issc transposons


A method for designing circular permuted proteins using two engineered mu transposons for easy construction of random circular permuted proteins, the two designed transposons being mucp-isc (mu circular permutation transposon with integrated start codon) and mucp-issc (mu circular permutation transposon with integrated start and stop codon).. .
New York University


03/24/16
20160083748 

Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof


Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (orf) for a protein under the control of regulatory sequences which direct expression of the product in cell, which orf has been modified to preferentially increase expression levels in a selected tissue, wherein the modified orf is characterized by a triplet frequency of any one of tables 3-12, 16 or 17..
The Trustees Of The University Of Pennsylvania


03/24/16
20160083462 

Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same


The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (cir) genes.
Roger Williams Hospital


03/24/16
20160083393 

Compounds for treatment of pain


The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. Compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain..

03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/03/16
20160058680 

Method and apparatus of manufacturing cosmetic products for regenerating skin cell


A method of manufacturing a cosmetic product for regenerating a skin cell including generating a water into a magnetized hexagonal water through a magnetized hexagonal water generator, separating a body fat stem cell from a body skin through a first extractor to extract a natural protein from a culture medium of a stem cell including the adipose-derived stem cell, extracting at least one skin beneficial ingredient from the culture medium of the stem cell through a second extractor, extracting a plant extract from at least one plant of a pomegranate, red ginseng, liquorice, ginseng seed, milk vetch, poria cocos, scutellaria, portulaca oleracea, pleuropterus multiflorus, angelica, angelica tenuissima, coix, codonopsis, morus alba and cucumber, and mixing the magnetized hexagonal water, natural protein, the at least one skin beneficial ingredient and the at least one plant extract through a mixer to manufacture a cosmetic product for regenerating a skin cell.. .
Aphrozone Co., Ltd.


02/25/16
20160051659 

Gene optimized hantaan virus m segment dna vaccine for hemorrhagic fever with renal syndrome


A synthetic, codon-optimized hantaan virus (htnv) full-length m gene open reading frame that consists of a unique nucleotide sequence encoding htnv proteins. This synthetic gene was cloned into a plasmid to form the first optimized htnv full-length m gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized puumala virus (puuv) dna vaccine.
Government Of The United States, As Represented By The Secretary Of The Army


02/11/16
20160039894 

Ptd-smad7 therapeutics


The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
The Regents Of The University Of Colorado, A Body Corporate


02/11/16
20160039837 

Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same


Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs..
Johnson Matthey Public Limited Company


02/04/16
20160032254 

Aav vectors produced by insect cells comprising rep52 and rep78 coding sequences with differential codon biases


The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors..
Uniqure Ip B.v.


02/04/16
20160030419 

Once-a-day oxycodone formulations


The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.


01/28/16
20160022805 

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza


Described herein is the generation of optimized h5n 1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/21/16
20160017341 

Universal protein overexpression tag comprising ramp function, and application thereof


Provided is a ramp tag capable of solving instability in translation rate resulting from poor compatibility between codons in a foreign gene and a host when expressing a recombinant protein in e. Coli.
Industry Foundation Of Chonnam National University


01/21/16
20160016965 

Novel mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereof


An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects.
West Virginia University


01/21/16
20160015802 

Compositions and methods to treat aids


Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins.
University Of Massachusetts


01/14/16
20160010111 

Production methods


The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities.
Glaxo Group Limited


01/07/16
20160002616 

Genes with codon mutations encoding xylanase


The present disclosure provides for a polynucleotide sequences encoding a xylanase. More specifically, the present disclosure provides for polynucleotide sequences with codon mutations encoding a xylanase..
Basf Enzymes Llc


12/24/15
20150368622 

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization


Described herein are rsv polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against rsv..
The United Of America, As Represented By Secretary, Department Of Health And Human Services


12/17/15
20150361158 

Optimized factor viii gene


The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. .
Biogen Ma Inc.


12/10/15
20150353938 

Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)


This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cdna encoding the rpgr protein.
Applied Genetic Technologies Corporation


12/10/15
20150352136 

Novel aminoglycosides and uses thereof in the treatment of genetic disorders


A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders..
Technion Research & Development Foundation Limited


12/03/15
20150344930 

Codon-optimized recombinant phage and methods of using same


Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker.
Sample6 Technologies, Inc.


11/26/15
20150335759 

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof


The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride.
Kempharm, Inc.


11/26/15
20150335639 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


11/19/15
20150329854 

Method of synthesis of gene library using codon randomization and mutagenesis


Proposed is a method of easily finding an error during analysis of various library sequences of nucleic acid base sequences after synthesizing a gene library using a combination of three nucleic acid base sequences (codon) translated into the same protein. This shows that it is possible to create a gene library having the same protein sequence but different nucleic acid base sequences.
Celemics, Inc.


11/19/15
20150328247 

Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same


Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof..
Ramot At Tel-aviv University Ltd.


11/12/15
20150320686 

Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer


The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.

10/29/15
20150307912 

Site-specific incorporation of phosphoserine into proteins in escherichia coli


Nucleic acids encoding mutant elongation factor proteins (ef-sep), phosphoseryl-trna synthetase (seprs), and phosphoseryl-trna (trnasep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, seprs preferentially aminoacylates trnasep with o-phosphoserine and the trnasep recognizes at least one codon such as a stop codon.
Yale University


10/15/15
20150293023 

Systems and methods for measuring translation of target proteins in cells


The present invention relates to systems and methods for measuring the rate of translation of a target protein in cells, which are based on the detection of translation of one or more predetermined codon pairs during synthesis of the target protein. The detection is provided by a fret signal emitted from labeled trna molecules which are juxtaposed during synthesis of the protein..

10/08/15
20150284402 

Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof


Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein..

10/08/15
20150283267 

Vectors for liver-directed gene therapy of hemophilia and methods and use thereof


The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor ix or factor viii genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor ix or factor viii genes are also disclosed.

10/01/15
20150273026 

Clinical applications for recombinant human mxa protein


Full length mxa constructs and truncated mxa constructs produce human mxa protein in e. Coli.
Rapid Pathogen Screening, Inc.


09/24/15
20150265598 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/24/15
20150265597 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/24/15
20150265537 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150259721 

Cell lines


There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses pylrs and trnapyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of trnapyl expression on cell viability and/or cell growth is reduced or eliminated.. .
Allozyne, Inc.


09/17/15
20150259664 

Proteolytic inactivation of select proteins in bacterial extracts for improved expression


The present disclosure provides modified proteins that are capable of being cleaved by the protease ompt1. The proteins can be modified in an exposed surface motif to incorporate ompt1 cleavage sites.
Sutro Biopharma, Inc.


09/17/15
20150259355 

Process for improved opioid synthesis


Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of apis and pharmaceutical dosage forms; and uses of said apis and pharmaceutical dosage forms in the treatment of medical conditions.. .
Rhodes Technologies


09/17/15
20150258186 

Nucleic acid molecule vaccine compositions and uses thereof


The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.


09/17/15
20150258090 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150258089 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150258086 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/10/15
20150252052 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


09/10/15
20150250866 

Live attenuated antigenically marked classical swine fever vaccine


Controlling classical swine fever virus (csfv) involves either prophylactic vaccination or non-vaccination and elimination of infected herds depending on the epidemiological situation. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement “stamping out” measures.
The United States Of America, As Represented By The Secretary Of Agriculture


09/10/15
20150250151 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.


09/03/15
20150246961 

Method for the expression of polypeptides using modified nucleic acids


Herein is reported a method for recombinantly producing a polypeptide in a cell comprising the step of cultivating a cell which comprises a nucleic acid encoding the polypeptide, and recovering the polypeptide from the cell or the cultivation medium, wherein each of the amino acid residues of the polypeptide is encoded by at least one codon, whereby the different codons encoding the same amino acid residue are combined in one group and each of the codons in a group is defined by a specific usage frequency within the group, whereby the sum of the specific usage frequencies of all codons in one group is 100%, and wherein the usage frequency of a codon in the polypeptide encoding nucleic acid is about the same as its specific usage frequency within its group.. .
Hoffmann-la Roche Inc.


09/03/15
20150246083 

Genetically modified probiotic for the treatment of phenylketonuria (pku) disease


A gmp adapted to provide the pal gene for the treatment of pku when administered orally. The gmp of the present invention may include a probiotic, a pal gene to be expressed using the probiotic, wherein the pal gene is functionally attached to a promoter and a ribosome binding site, and may be codon-optimized for expression in a certain host organism.
University Of North Texas


09/03/15
20150246034 

Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia


The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subject's body faster than it is being absorbed..
Mallinckrodt Llc




Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3611

4493

0 - 1 - 104